NASDAQ Further Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements

KINDERHOOK, N.Y. -- (BUSINESS WIRE) -- March 27, 2009 -- American Bio Medica Corporation (NASDAQ:ABMC) has received notice from the NASDAQ OMX Group ("NASDAQ") that NASDAQ has determined to extend its suspension of the bid price and market value of publicly held shares requirements, and that enforcement of these rules is now scheduled to resume on Monday, July 20, 2009.

All companies in a compliance period for a bid price or market value of publicly held shares concern will continue to be "frozen" and remain at the same stage of the process with respect to these rules. ABMC can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by achieving a $1.00 closing bid price for a minimum of 10 consecutive trading days.

Although NASDAQ has not provided ABMC with a new compliance date, since ABMC had 22 calendar days remaining in its compliance period for its bid price deficiency prior to NASDAQ’s initial temporary suspension, ABMC estimates they will have until August 18, 2009 to regain compliance.

The NASDAQ notice has no effect on the listing of ABMC’s common stock on The NASDAQ Capital Market at this time.

For more information on American Bio Medica Corporation or its products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, Rapid TEC®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® products test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer